

"The wearable medical device that warns and monitors seizures continuously"



Epilepsy, is one of the most common neurological diseases worldwide. It is characterized by abnormal brain activity causing seizures or unusual behavior, sensations and sometimes loss of awareness. It carries neurological, cognitive, psychological and social consequences. There is a lack of predictive tools, which would allow the patient to move to a safe space to prevent accidents and injuries because of the seizure.







3X premature risk



70% people could be seizure-free with appropriate diagnosis and treatment

THE SOLUTION



MJN-SERAS is a discreet, non-invasive and wearable medical device that is able to predict an epilepsy seizure before it occurs and monitor it.

- Earpiece that sits in the ear like a hearing air, which is able to read the user's electroencephalogram in real time.
- A mobile application that contains an artificial intelligence algorithm. This application, which takes a reading of the data from the earpiece using Bluetooth, is capable of emitting a warning signal.

KEY BENEFITS



→ REAL-TIME risk of seizure evaluation.



WEARABLE custom-fit earpiece, discrete and noninvasive.



PERSONALIZED algorithm that records brain activity and uses Big Data.



OBJECTIVE reduce accidents, falls and injuries from unpredictable seizures. Reduce the emotional impact of epilepsy.



REDUCE economic impact through prevention.

MILESTONES

2014 Foundation

2016 Proof of Concept

2017 MVP

2018 EU Patent Application

2018 Final Prototype

2020 CE mark / Market Launch

2021 Break even

FUNDS RAISED



- 3% FFF round
- 18% Investment round
- 3% MWC prize
- 5% Clínica Corachan agreement
- 5% ENISA
- 12% Retos Colaboración
- 54% H2020 SME Instrument Phase II

KEYMETRICS

1.750€ Price device

84bn€ Global epilepsy market (2024)

0,6% Penetration rate

55M€ projected revenue 2024

75.000 users 2024

FUNDS DESTINATION



- 25% Prototype scale-up
- 10% Marketing
- 25% Analytical & pre-clinical validation
- 15% IP Protection
- 10% R&D
- 15% Commercialization

ACCELERATION PROGRAMS

□-L∧B SOBRE CAPITAL. (2018)



MedTe (2018)





Tech4Health (2017)

MANAGING TEAM



David Blánquez Co-Founder & CEO - CTO Co-Founder & CFO



Salva Gutiérrez in



Xavier Raurich Co-Founder & COO in















